-
1
-
-
84925307652
-
Comparative therapeutic effects of radioactive and chemical agents in neoplastic diseases of the hemopoietic system
-
Brues AM, Jacobson LO. Comparative therapeutic effects of radioactive and chemical agents in neoplastic diseases of the hemopoietic system. Am J Roentgenol Radium Ther 1947;58:774-82.
-
(1947)
Am J Roentgenol Radium Ther
, vol.58
, pp. 774-782
-
-
Brues, AM1
Jacobson, LO.2
-
2
-
-
78651010566
-
Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid
-
Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-93.
-
(1948)
N Engl J Med
, vol.238
, pp. 787-793
-
-
Farber, S1
Diamond, LK.2
-
3
-
-
37049222627
-
Endocrine control of prostatic cancer
-
Huggins C. Endocrine control of prostatic cancer. Science 1943;97:541-4.
-
(1943)
Science
, vol.97
, pp. 541-544
-
-
Huggins, C.1
-
4
-
-
50549191387
-
Tumor inhibitory effect of L-asparaginase from Escherichia coli
-
Mashburn LT, Wriston JC Jr. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964;105:450-2.
-
(1964)
Arch Biochem Biophys
, vol.105
, pp. 450-452
-
-
Mashburn, LT1
Wriston, JC2
-
5
-
-
65649090993
-
BRAF signaling and targeted therapies in melanoma
-
Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 2009;23:529-45.
-
(2009)
Hematol Oncol Clin North Am
, vol.23
, pp. 529-545
-
-
Dhomen, N1
Marais, R.2
-
6
-
-
58149398623
-
Translation of the Philadelphia chromosome into therapy for CML
-
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-17.
-
(2008)
Blood
, vol.112
, pp. 4808-4817
-
-
Druker, BJ.1
-
7
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, DJ1
Leyland-Jones, B2
Shak, S3
-
8
-
-
33847396951
-
Small molecule inhibitors of Stat3 signaling pathway
-
Deng J, Grande F, Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 2007;7:91-107.
-
(2007)
Curr Cancer Drug Targets
, vol.7
, pp. 91-107
-
-
Deng, J1
Grande, F2
Neamati, N.3
-
9
-
-
27744536543
-
Targeting hypoxia and angiogenesis through HIF-1alpha inhibition
-
Diaz-Gonzalez JA, Russell J, Rouzaut A, GilBazo I, Montuenga L. Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther 2005;4:1055-62.
-
(2005)
Cancer Biol Ther
, vol.4
, pp. 1055-1062
-
-
Diaz-Gonzalez, JA1
Russell, J2
Rouzaut, A3
GilBazo, I4
Montuenga, L.5
-
10
-
-
58149401867
-
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
-
Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs 2008;17:1865-82.
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 1865-1882
-
-
Patel, S1
Player, MR.2
-
11
-
-
33745699614
-
Mutational analysis of MYC in common epithelial cancers and acute leukemias
-
Lee JW, Soung YH, Kim SY, et al. Mutational analysis of MYC in common epithelial cancers and acute leukemias. APMIS 2006;114:436-9.
-
(2006)
APMIS
, vol.114
, pp. 436-439
-
-
Lee, JW1
Soung, YH2
Kim, SY3
-
12
-
-
0033551374
-
MYC oncogenes and human neoplastic disease
-
Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004-16.
-
(1999)
Oncogene
, vol.18
, pp. 3004-3016
-
-
Nesbit, CE1
Tersak, JM2
Prochownik, EV.3
-
13
-
-
0034653998
-
c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover
-
Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000;95:2104-10.
-
(2000)
Blood
, vol.95
, pp. 2104-2110
-
-
Bahram, F1
von der Lehr, N2
Cetinkaya, C3
Larsson, LG.4
-
14
-
-
0027275755
-
Point mutations in the c-Myc transactivation domain are common in Burkitt’s lymphoma and mouse plasmacytomas
-
Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt’s lymphoma and mouse plasmacytomas. Nat Genet 1993;5:56-61.
-
(1993)
Nat Genet
, vol.5
, pp. 56-61
-
-
Bhatia, K1
Huppi, K2
Spangler, G3
Siwarski, D4
Iyer, R5
Magrath, I.6
-
15
-
-
0028305664
-
Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas
-
Clark HM, Yano T, Otsuki T, Jaffe ES, Shibata D, Raffeld M. Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res 1994;54:3383-6.
-
(1994)
Cancer Res
, vol.54
, pp. 3383-3386
-
-
Clark, HM1
Yano, T2
Otsuki, T3
Jaffe, ES4
Shibata, D5
Raffeld, M.6
-
16
-
-
0028115718
-
Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo
-
Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 1994;9:59-70.
-
(1994)
Oncogene
, vol.9
, pp. 59-70
-
-
Pulverer, BJ1
Fisher, C2
Vousden, K3
Littlewood, T4
Evan, G5
Woodgett, JR.6
-
17
-
-
0027220503
-
Clustered mutations in the second exon of the MYC gene in sporadic Burkitt’s lymphoma
-
Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt’s lymphoma. Oncogene 1993;8:2741-8.
-
(1993)
Oncogene
, vol.8
, pp. 2741-2748
-
-
Yano, T1
Sander, CA2
Clark, HM3
Dolezal, MV4
Jaffe, ES5
Raffeld, M.6
-
18
-
-
0034059667
-
c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt’s lymphoma cells
-
Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt’s lymphoma cells. Mol Cell Biol 2000;20:2423-35.
-
(2000)
Mol Cell Biol
, vol.20
, pp. 2423-2435
-
-
Gregory, MA1
Hann, SR.2
-
19
-
-
67749122122
-
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
-
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 550-562
-
-
Engelman, JA.1
-
20
-
-
77949366910
-
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase
-
Kantarjian HM, Cortes J, La Rosee P, Hochhaus A. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 2010;116:1419-30.
-
(2010)
Cancer
, vol.116
, pp. 1419-1430
-
-
Kantarjian, HM1
Cortes, J2
La Rosee, P3
Hochhaus, A.4
-
23
-
-
0842265178
-
Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
-
Ross DM, Hughes TP. Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer 2004;90:12-9.
-
(2004)
Br J Cancer
, vol.90
, pp. 12-19
-
-
Ross, DM1
Hughes, TP.2
-
24
-
-
35748985280
-
Protein kinase inhibitors: structural insights into selectivity
-
Thaimattam R, Banerjee R, Miglani R, Iqbal J. Protein kinase inhibitors: structural insights into selectivity. Curr Pharm Des 2007;13:2751-65.
-
(2007)
Curr Pharm Des
, vol.13
, pp. 2751-2765
-
-
Thaimattam, R1
Banerjee, R2
Miglani, R3
Iqbal, J.4
-
25
-
-
33748145149
-
Mechanism of transcriptional activation by the Myc oncoproteins
-
Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol 2006;16:242-52.
-
(2006)
Semin Cancer Biol
, vol.16
, pp. 242-252
-
-
Cowling, VH1
Cole, MD.2
-
26
-
-
0034130734
-
Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis
-
Huang Z. Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis. Pharmacol Ther 2000;86:201-15.
-
(2000)
Pharmacol Ther
, vol.86
, pp. 201-215
-
-
Huang, Z.1
-
27
-
-
0030028728
-
Principles of protein– protein interactions
-
Jones S, Thornton JM. Principles of protein– protein interactions. Proc Natl Acad Sci U S A 1996;93:13-20.
-
(1996)
Proc Natl Acad Sci U S A
, vol.93
, pp. 13-20
-
-
Jones, S1
Thornton, JM.2
-
29
-
-
41149113439
-
c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle
-
Wang H, Mannava S, Grachtchouk V, et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 2008;27:1905-15.
-
(2008)
Oncogene
, vol.27
, pp. 1905-1915
-
-
Wang, H1
Mannava, S2
Grachtchouk, V3
-
30
-
-
0842303173
-
Reversibility of oncogene-induced cancer
-
Felsher DW. Reversibility of oncogene-induced cancer. Curr Opin Genet Dev 2004;14:37-42.
-
(2004)
Curr Opin Genet Dev
, vol.14
, pp. 37-42
-
-
Felsher, DW.1
-
31
-
-
0033180211
-
Reversible tumorigenesis by MYC in hematopoietic lineages
-
Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
-
(1999)
Mol Cell
, vol.4
, pp. 199-207
-
-
Felsher, DW1
Bishop, JM.2
-
32
-
-
0037025201
-
Sustained loss of a neoplastic phenotype by brief inactivation of MYC
-
Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-4.
-
(2002)
Science
, vol.297
, pp. 102-104
-
-
Jain, M1
Arvanitis, C2
Chu, K3
-
33
-
-
10944258521
-
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation
-
Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004;6:577-86.
-
(2004)
Cancer Cell
, vol.6
, pp. 577-586
-
-
Boxer, RB1
Jang, JW2
Sintasath, L3
Chodosh, LA.4
-
34
-
-
0038107350
-
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations
-
Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003;101: 2797-803.
-
(2003)
Blood
, vol.101
, pp. 2797-2803
-
-
Karlsson, A1
Giuriato, S2
Tang, F3
Fung-Weier, J4
Levan, G5
Felsher, DW.6
-
35
-
-
53349103292
-
Modelling Myc inhibition as a cancer therapy
-
Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008;455:679-83.
-
(2008)
Nature
, vol.455
, pp. 679-683
-
-
Soucek, L1
Whitfield, J2
Martins, CP3
-
36
-
-
0035118130
-
A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation
-
Bazarov AV, Adachi S, Li SF, Mateyak MK, Wei S, Sedivy JM. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res 2001;61:1178-86.
-
(2001)
Cancer Res
, vol.61
, pp. 1178-1186
-
-
Bazarov, AV1
Adachi, S2
Li, SF3
Mateyak, MK4
Wei, S5
Sedivy, JM.6
-
37
-
-
34748867198
-
Improved low molecular weight Myc–Max inhibitors
-
Wang H, Hammoudeh DI, Follis AV, et al. Improved low molecular weight Myc–Max inhibitors. Mol Cancer Ther 2007;6:2399-408.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 2399-2408
-
-
Wang, H1
Hammoudeh, DI2
Follis, AV3
-
39
-
-
0025167156
-
The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation
-
Smith MJ, Charron-Prochownik DC, Prochownik EV. The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation. Mol Cell Biol 1990;10:5333-9.
-
(1990)
Mol Cell Biol
, vol.10
, pp. 5333-5339
-
-
Smith, MJ1
Charron-Prochownik, DC2
Prochownik, EV.3
-
40
-
-
0142057146
-
Low molecular weight inhibitors of Myc–Max interaction and function
-
Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc–Max interaction and function. Oncogene 2003;22:6151-9.
-
(2003)
Oncogene
, vol.22
, pp. 6151-6159
-
-
Yin, X1
Giap, C2
Lazo, JS3
Prochownik, EV.4
-
41
-
-
0028916599
-
A hot spot of binding energy in a hormone-receptor interface
-
Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 1995;267:383-6.
-
(1995)
Science
, vol.267
, pp. 383-386
-
-
Clackson, T1
Wells, JA.2
-
42
-
-
20444486559
-
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
-
Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
-
(2005)
Nature
, vol.435
, pp. 677-681
-
-
Oltersdorf, T1
Elmore, SW2
Shoemaker, AR3
-
43
-
-
67649362253
-
Regulated cell death pathways: new twists in modulation of BCL2 family function
-
Sasi N, Hwang M, Jaboin J, Csiki I, Lu B. Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol Cancer Ther 2009;8:1421-9.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1421-1429
-
-
Sasi, N1
Hwang, M2
Jaboin, J3
Csiki, I4
Lu, B.5
-
44
-
-
0037133575
-
Smallmolecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts
-
Berg T, Cohen SB, Desharnais J, et al. Smallmolecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A 2002;99:3830-5.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 3830-3835
-
-
Berg, T1
Cohen, SB2
Desharnais, J3
-
45
-
-
42149091567
-
Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine
-
Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem 2007;2:627-30.
-
(2007)
ChemMedChem
, vol.2
, pp. 627-630
-
-
Kiessling, A1
Wiesinger, R2
Sperl, B3
Berg, T.4
-
46
-
-
33746239002
-
Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules
-
Kiessling A, Sperl B, Hollis A, Eick D, Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 2006;13:745-51.
-
(2006)
Chem Biol
, vol.13
, pp. 745-751
-
-
Kiessling, A1
Sperl, B2
Hollis, A3
Eick, D4
Berg, T.5
-
47
-
-
0035984722
-
Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions
-
Galarneau A, Primeau M, Trudeau LE, Michnick SW. Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. Nat Biotechnol 2002;20:619-22.
-
(2002)
Nat Biotechnol
, vol.20
, pp. 619-622
-
-
Galarneau, A1
Primeau, M2
Trudeau, LE3
Michnick, SW.4
-
48
-
-
0037133629
-
Protein-protein interactions monitored in mammalian cells via complementation of betalactamase enzyme fragments
-
Wehrman T, Kleaveland B, Her JH, Balint RF, Blau HM. Protein-protein interactions monitored in mammalian cells via complementation of betalactamase enzyme fragments. Proc Natl Acad Sci U S A 2002;99:3469-74.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 3469-3474
-
-
Wehrman, T1
Kleaveland, B2
Her, JH3
Balint, RF4
Blau, HM.5
-
49
-
-
34748851858
-
Application of beta-lactamase enzyme complementation to the high-throughput screening of toll-like receptor signaling inhibitors
-
Lee HK, Brown SJ, Rosen H, Tobias PS. Application of beta-lactamase enzyme complementation to the high-throughput screening of toll-like receptor signaling inhibitors. Mol Pharmacol 2007;72:868-75.
-
(2007)
Mol Pharmacol
, vol.72
, pp. 868-875
-
-
Lee, HK1
Brown, SJ2
Rosen, H3
Tobias, PS.4
-
50
-
-
0343550320
-
Two comparisons of the performance of positional scanning and deletion synthesis for the identification of active constituents in mixture combinatorial libraries
-
Boger DL, Lee JK, Goldberg J, Jin Q. Two comparisons of the performance of positional scanning and deletion synthesis for the identification of active constituents in mixture combinatorial libraries. J Org Chem 2000;65:1467-74.
-
(2000)
J Org Chem
, vol.65
, pp. 1467-1474
-
-
Boger, DL1
Lee, JK2
Goldberg, J3
Jin, Q.4
-
51
-
-
33644762865
-
A credit-card library approach for disrupting protein-protein interactions
-
Xu Y, Shi J, Yamamoto N, Moss JA, Vogt PK, Janda KD. A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem 2006;14:2660-73.
-
(2006)
Bioorg Med Chem
, vol.14
, pp. 2660-2673
-
-
Xu, Y1
Shi, J2
Yamamoto, N3
Moss, JA4
Vogt, PK5
Janda, KD.6
-
52
-
-
40249102008
-
Disruption of the MYC transcriptional function by a smallmolecule antagonist of MYC/MAX dimerization
-
Lu X, Vogt PK, Boger DL, Lunec J. Disruption of the MYC transcriptional function by a smallmolecule antagonist of MYC/MAX dimerization. Oncol Rep 2008;19:825-30.
-
(2008)
Oncol Rep
, vol.19
, pp. 825-830
-
-
Lu, X1
Vogt, PK2
Boger, DL3
Lunec, J.4
-
53
-
-
0035912763
-
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis
-
Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 2001;98:7319-24.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 7319-7324
-
-
Bowman, T1
Broome, MA2
Sinibaldi, D3
-
54
-
-
0030849451
-
Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination
-
Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997;8:1039-48.
-
(1997)
Cell Growth Differ
, vol.8
, pp. 1039-1048
-
-
Mateyak, MK1
Obaya, AJ2
Adachi, S3
Sedivy, JM.4
-
55
-
-
56049097680
-
Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules
-
Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol 2008;15:1149-55.
-
(2008)
Chem Biol
, vol.15
, pp. 1149-1155
-
-
Follis, AV1
Hammoudeh, DI2
Wang, H3
Prochownik, EV4
Metallo, SJ.5
-
56
-
-
67650523478
-
Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc
-
Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc 2009;131:7390-401.
-
(2009)
J Am Chem Soc
, vol.131
, pp. 7390-7401
-
-
Hammoudeh, DI1
Follis, AV2
Prochownik, EV3
Metallo, SJ.4
-
57
-
-
34249022980
-
GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D
-
Richmond NJ, Abrams CA, Wolohan PR, Abrahamian E, Willett P, Clark RD. GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J Comput Aided Mol Des 2006;20:567-87.
-
(2006)
J Comput Aided Mol Des
, vol.20
, pp. 567-587
-
-
Richmond, NJ1
Abrams, CA2
Wolohan, PR3
Abrahamian, E4
Willett, P5
Clark, RD.6
-
58
-
-
33947580381
-
A marriage made in torsional space: using GALAHAD models to drive pharmacophore multiplet searches
-
Shepphird JK, Clark RD. A marriage made in torsional space: using GALAHAD models to drive pharmacophore multiplet searches. J Comput Aided Mol Des 2006;20:763-71.
-
(2006)
J Comput Aided Mol Des
, vol.20
, pp. 763-771
-
-
Shepphird, JK1
Clark, RD.2
-
59
-
-
13844312649
-
ZINC: a free database of commercially available compounds for virtual screening
-
Irwin JJ, Shoichet BK. ZINC: a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45:177-82.
-
(2005)
J Chem Inf Model
, vol.45
, pp. 177-182
-
-
Irwin, JJ1
Shoichet, BK.2
-
60
-
-
0034541821
-
The human CYP3A subfamily: practical considerations
-
Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000;32:339-61.
-
(2000)
Drug Metab Rev
, vol.32
, pp. 339-361
-
-
Wrighton, SA1
Schuetz, EG2
Thummel, KE3
Shen, DD4
Korzekwa, KR5
Watkins, PB.6
-
62
-
-
42049098451
-
Multivalent drug design and inhibition of cholera toxin by specific and transient protein-ligand interactions
-
Liu J, Begley D, Mitchell DD, Verlinde CL, Varani G, Fan E. Multivalent drug design and inhibition of cholera toxin by specific and transient protein-ligand interactions. Chem Biol Drug Des 2008;71:408-19.
-
(2008)
Chem Biol Drug Des
, vol.71
, pp. 408-419
-
-
Liu, J1
Begley, D2
Mitchell, DD3
Verlinde, CL4
Varani, G5
Fan, E.6
-
63
-
-
0035853279
-
Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc
-
Fieber W, Schneider ML, Matt T, Krautler B, Konrat R, Bister K. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. J Mol Biol 2001;307:1395-410.
-
(2001)
J Mol Biol
, vol.307
, pp. 1395-1410
-
-
Fieber, W1
Schneider, ML2
Matt, T3
Krautler, B4
Konrat, R5
Bister, K.6
-
64
-
-
0037462459
-
X-ray structures of Myc– Max and Mad-Max recognizing DNA: molecular bases of regulation by proto-oncogenic transcription factors
-
Nair SK, Burley SK. X-ray structures of Myc– Max and Mad-Max recognizing DNA: molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003;112:193-205.
-
(2003)
Cell
, vol.112
, pp. 193-205
-
-
Nair, SK1
Burley, SK.2
-
65
-
-
25144472591
-
Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling
-
Uversky VN, Oldfield CJ, Dunker AK. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J Mol Recognit 2005;18:343-84.
-
(2005)
J Mol Recognit
, vol.18
, pp. 343-384
-
-
Uversky, VN1
Oldfield, CJ2
Dunker, AK.3
-
66
-
-
77949762977
-
A comprehensive resource of interacting protein regions for refining human transcription factor networks
-
Miyamoto-Sato E, Fujimori S, Ishizaka M, et al. A comprehensive resource of interacting protein regions for refining human transcription factor networks. PLoS One 2010;5:e9289.
-
(2010)
PLoS One
, vol.5
, pp. e9289
-
-
Miyamoto-Sato, E1
Fujimori, S2
Ishizaka, M3
-
67
-
-
77249105931
-
Protein intrinsic disorder and oligomericity in cell signaling
-
Sigalov AB. Protein intrinsic disorder and oligomericity in cell signaling. Mol Biosyst 2010;6:451-61.
-
(2010)
Mol Biosyst
, vol.6
, pp. 451-461
-
-
Sigalov, AB.1
-
68
-
-
58849157916
-
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-4ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice
-
Guo J, Parise RA, Joseph E, et al. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-4ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol 2009;63:615-25.
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 615-625
-
-
Guo, J1
Parise, RA2
Joseph, E3
-
69
-
-
77749270618
-
Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus
-
Giordano A. Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus. Curr Opin Drug Discov Devel 2010;13:159-68.
-
(2010)
Curr Opin Drug Discov Devel
, vol.13
, pp. 159-168
-
-
Giordano, A.1
-
70
-
-
72049114146
-
Meta-analysis of five randomized clinical trials comparing sirolimusversus paclitaxel-eluting stents in patients with diabetes mellitus
-
Zhang F, Dong L, Ge J. Meta-analysis of five randomized clinical trials comparing sirolimusversus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol 2010;105:64-8.
-
(2010)
Am J Cardiol
, vol.105
, pp. 64-68
-
-
Zhang, F1
Dong, L2
Ge, J.3
-
71
-
-
33744488782
-
Rat carotid arteriotomy: c-myc is involved in negative remodelling and apoptosis
-
De Feo M, Forte A, Onorati F, et al. Rat carotid arteriotomy: c-myc is involved in negative remodelling and apoptosis. J Cardiovasc Med (Hagerstown) 2006;7:61-7.
-
(2006)
J Cardiovasc Med (Hagerstown)
, vol.7
, pp. 61-67
-
-
De Feo, M1
Forte, A2
Onorati, F3
-
72
-
-
20644469260
-
c-Myc antisense oligonucleotides preserve smooth muscle differentiation and reduce negative remodelling following rat carotid arteriotomy
-
Forte A, Galderisi U, De Feo M, et al. c-Myc antisense oligonucleotides preserve smooth muscle differentiation and reduce negative remodelling following rat carotid arteriotomy. J Vasc Res 2005;42:214-25.
-
(2005)
J Vasc Res
, vol.42
, pp. 214-225
-
-
Forte, A1
Galderisi, U2
De Feo, M3
-
73
-
-
12244259715
-
Antisense therapy for restenosis following percutaneous coronary intervention
-
Kipshidze N, Tsapenko M, Iversen P, Burger D. Antisense therapy for restenosis following percutaneous coronary intervention. Expert Opin Biol Ther 2005;5:79-89.
-
(2005)
Expert Opin Biol Ther
, vol.5
, pp. 79-89
-
-
Kipshidze, N1
Tsapenko, M2
Iversen, P3
Burger, D.4
-
74
-
-
38449100932
-
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
-
Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-8.
-
(2007)
Curr Opin Ophthalmol
, vol.18
, pp. 502-508
-
-
Andreoli, CM1
Miller, JW.2
-
75
-
-
34547119296
-
Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema
-
Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007;21:245-57.
-
(2007)
BioDrugs
, vol.21
, pp. 245-257
-
-
Emerson, MV1
Lauer, AK.2
-
76
-
-
65549159481
-
Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic retinopathy
-
Figueroa MS, Contreras I, Noval S. Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic retinopathy. Curr Diabetes Rev 2009;5:52-6.
-
(2009)
Curr Diabetes Rev
, vol.5
, pp. 52-56
-
-
Figueroa, MS1
Contreras, I2
Noval, S.3
-
77
-
-
0025763419
-
Max: a helixloop-helix zipper protein that forms a sequencespecific DNA-binding complex with Myc
-
Blackwood EM, Eisenman RN. Max: a helixloop-helix zipper protein that forms a sequencespecific DNA-binding complex with Myc. Science 1991;251:1211-7.
-
(1991)
Science
, vol.251
, pp. 1211-1217
-
-
Blackwood, EM1
Eisenman, RN.2
-
79
-
-
0032554768
-
Lack of transcriptional repression by max homodimers
-
Yin X, Grove L, Prochownik EV. Lack of transcriptional repression by max homodimers. Oncogene 1998;16:2629-37.
-
(1998)
Oncogene
, vol.16
, pp. 2629-2637
-
-
Yin, X1
Grove, L2
Prochownik, EV.3
-
80
-
-
0028937378
-
Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice
-
Lindeman GJ, Harris AW, Bath ML, Eisenman RN, Adams JM. Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. Oncogene 1995;10:1013-7.
-
(1995)
Oncogene
, vol.10
, pp. 1013-1017
-
-
Lindeman, GJ1
Harris, AW2
Bath, ML3
Eisenman, RN4
Adams, JM.5
-
81
-
-
0027175983
-
Transfected wild-type and mutant max regulate cell growth and differentiation of murine erythroleukemia cells
-
Cogliati T, Dunn BK, Bar-Ner M, Cultraro CM, Segal S. Transfected wild-type and mutant max regulate cell growth and differentiation of murine erythroleukemia cells. Oncogene 1993;8:1263-8.
-
(1993)
Oncogene
, vol.8
, pp. 1263-1268
-
-
Cogliati, T1
Dunn, BK2
Bar-Ner, M3
Cultraro, CM4
Segal, S.5
-
82
-
-
0027081907
-
Transcriptional activities of the Myc and Max proteins in mammalian cells
-
Kretzner L, Blackwood EM, Eisenman RN. Transcriptional activities of the Myc and Max proteins in mammalian cells. Curr Top Microbiol Immunol 1992;182:435-43.
-
(1992)
Curr Top Microbiol Immunol
, vol.182
, pp. 435-443
-
-
Kretzner, L1
Blackwood, EM2
Eisenman, RN.3
-
83
-
-
11644261806
-
Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function
-
Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-62.
-
(1998)
J Comput Chem
, vol.19
, pp. 1639-1662
-
-
Morris, GM1
Goodsell, DS2
Halliday, RS3
-
85
-
-
11144229113
-
Virtual screening of human 5-aminoimidazole4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors
-
Li C, Xu L, Wolan DW, Wilson IA, Olson AJ. Virtual screening of human 5-aminoimidazole4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors. J Med Chem 2004;47:6681-90.
-
(2004)
J Med Chem
, vol.47
, pp. 6681-6690
-
-
Li, C1
Xu, L2
Wolan, DW3
Wilson, IA4
Olson, AJ.5
-
86
-
-
27744552355
-
Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library
-
Dickerson TJ, Beuscher AET, Rogers CJ, et al. Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library. Biochemistry 2005;44:14845-53.
-
(2005)
Biochemistry
, vol.44
, pp. 14845-14853
-
-
Dickerson, TJ1
Beuscher, AET2
Rogers, CJ3
-
87
-
-
33644869304
-
Discovery of protein phosphatase 2C inhibitors by virtual screening
-
Rogers JP, Beuscher AET, Flajolet M, et al. Discovery of protein phosphatase 2C inhibitors by virtual screening. J Med Chem 2006;49:1658-67.
-
(2006)
J Med Chem
, vol.49
, pp. 1658-1667
-
-
Rogers, JP1
Beuscher, AET2
Flajolet, M3
-
88
-
-
64349094802
-
Discovery of novel myc-max heterodimer disruptors with a three-dimensional pharmacophore model
-
Mustata G, Follis AV, Hammoudeh DI, et al. Discovery of novel myc-max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem 2009;52:1247-50.
-
(2009)
J Med Chem
, vol.52
, pp. 1247-1250
-
-
Mustata, G1
Follis, AV2
Hammoudeh, DI3
|